Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 5
1991 7
1992 8
1993 13
1994 7
1995 25
1996 25
1997 23
1998 34
1999 46
2000 44
2001 71
2002 74
2003 92
2004 84
2005 96
2006 113
2007 95
2008 98
2009 116
2010 135
2011 140
2012 188
2013 167
2014 203
2015 254
2016 264
2017 262
2018 243
2019 127
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

2,692 results
Results by year
Filters applied: . Clear all
Page 1
Fusion protein linkers: property, design and functionality
Chen X, et al. Adv Drug Deliv Rev 2013 - Review. PMID 23026637 Free PMC article.
As an indispensable component of recombinant fusion proteins, linkers have shown increasing importance in the construction of stable, bioactive fusion proteins. ...
As an indispensable component of recombinant fusion proteins, linkers have shown increasing importance in the construction of stable, …
Self-encapsulation and controlled release of recombinant proteins using novel silica-forming peptides as fusion linkers.
Abdelhamid MAA, et al. Int J Biol Macromol 2019. PMID 30576734
Furthermore, the SFPs served as affinity linkers for the immobilization of recombinant proteins in silica. Interestingly, the SFP fusion proteins modulated silicic acid polycondensation and allowed for the self-immobilization of SFP fusion proteins in two distinct silica formulations depending on the ionic strength-precipitated silica particles or wet silica gel. ...These new findings provide a simple and reproducible route for silica hybrid formation for in situ stable auto-encapsulation and the sustained release of recombinant proteins with potential applications in biotechnology....
Furthermore, the SFPs served as affinity linkers for the immobilization of recombinant proteins in silica. Interestingly, the SFP fus …
Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
Davis J, et al. J Med Econ 2019. PMID 31094591
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients requires frequent injections. Extended half-life (EHL) products allow for prolonged dosing intervals, and so reduce this treatment burden. ...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients requires frequent injections. Extended h …
2,692 results
Jump to page
Feedback